A chemically inert drug can stimulate T cells in vitro by their T cell receptor in non-sensitised individuals

被引:46
作者
Engler, OB
Strasser, I
Naisbitt, DJ
Cerny, A
Pichler, WJ [1 ]
机构
[1] Univ Bern, Div Allergol, Clin Rheumatol & Clin Immunol Allergol, CH-3010 Bern, Switzerland
[2] Univ Liverpool, Dept Pharmacol, Liverpool L69 3GE, Merseyside, England
[3] Osped Civ, Med Clin, CH-6903 Lugano, Switzerland
基金
英国惠康基金;
关键词
drug; allergy; inert; T cells; immunmodulation; sulfamethoxazole; sulfamethoxazole-nitroso;
D O I
10.1016/j.tox.2003.12.008
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Drugs can interact with T cell receptors (TCR) after binding to peptide-MHC structures. This binding may involve the formation of a stable, covalent bond between a chemically reactive drug and MHC or the peptide embedded within. Alternatively, if the drug is chemically inert, the binding may be non-covalent and readily reversible. Both types of drug presentation account for a substantial number of adverse side effects to drugs. Presently no tests are available to predict the ability of chemically inert drugs to stimulate an immune response. Here we present data on the successful induction of a primary T cell immune response in vitro against a chemically inert drug using blood from healthy individuals, previously not exposed to the drug. Blood lymphocytes were stimulated by the chemically inert drug sulfamethoxazole and the protein-reactive drug-metabolite sulfamethoxazole-nitroso in the presence of IL-2.9/10 individuals reacted in response to sulfamethoxazole-nitroso, but only three reacted to the chemically inert compound sulfamethoxazole. Drug reactive T cells could be detected after 14-35 days of cell culture by drug-specific proliferation or cytotoxicity, which was MHC-restricted. These cells were CD4, CD8 positive or CD4/CD8 double positive and T cell clones generated secreted Th0 type cytokines. Drug interaction lead to down-regulation of specific TCR. These data confirm the ability of chemically inert drugs to stimulate certain T cells by their TCR and may provide the opportunity to screen new drugs for their ability to interact with TCRs. (C) 2004 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:47 / 56
页数:10
相关论文
共 28 条
[1]   Task Force Report: Future research needs for the prevention and management of immune-mediated drug hypersensitivity reactions [J].
Adkinson, NF ;
Essayan, D ;
Gruchalla, R ;
Haggerty, H ;
Kawabata, T ;
Sandler, JD ;
Updyke, L ;
Shear, NH ;
Wierda, D .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2002, 109 (03) :S461-S478
[2]   T-cell involvement in drug-induced acute generalized exanthematous pustulosis [J].
Britschgi, M ;
Steiner, UC ;
Schmid, S ;
Depta, JPH ;
Senti, G ;
Bircher, A ;
Burkhart, C ;
Yawalkar, N ;
Pichler, WJ .
JOURNAL OF CLINICAL INVESTIGATION, 2001, 107 (11) :1433-1441
[3]   CYTOTOXIC T-LYMPHOCYTE RESPONSE TO HEPATITIS-C VIRUS-DERIVED PEPTIDES CONTAINING THE HLA A2.1 BINDING MOTIF [J].
CERNY, A ;
MCHUTCHISON, JG ;
PASQUINELLI, C ;
BROWN, ME ;
BROTHERS, MA ;
GRABSCHEID, B ;
FOWLER, P ;
HOUGHTON, M ;
CHISARI, FV .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 95 (02) :521-530
[4]   SULFAMETHOXAZOLE IS METABOLIZED TO THE HYDROXYLAMINE IN HUMANS [J].
CRIBB, AE ;
SPIELBERG, SP .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 51 (05) :522-526
[5]   T cell involvement in cutaneous drug eruptions [J].
Hari, Y ;
Frutig-Schnyder, K ;
Hurni, M ;
Yawalkar, N ;
Zanni, MP ;
Schnyder, B ;
Kappeler, A ;
Von Greyerz, S ;
Braathen, LR ;
Pichler, WJ .
CLINICAL AND EXPERIMENTAL ALLERGY, 2001, 31 (09) :1398-1408
[6]   ACTIVATION AND EXPANSION OF HAPTEN-SPECIFIC AND PROTEIN-SPECIFIC T-HELPER CELLS FROM NONSENSITIZED MICE [J].
HAUSER, C ;
KATZ, SI .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (15) :5625-5628
[7]   MHC class I+/II- dendritic cells induce hapten-specific immune responses in vitro and in vivo [J].
Kolesaric, A ;
Stingl, G ;
ElbeBurger, A .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1997, 109 (04) :580-585
[8]   Studies on the sensitization of animals with simple chemical compounds [J].
Landsteiner, K ;
Jacobs, J .
JOURNAL OF EXPERIMENTAL MEDICINE, 1935, 61 (05) :643-U8
[9]  
MauriHellweg D, 1996, J IMMUNOL, V157, P1071
[10]  
MAURIHELLWEG D, 1995, J IMMUNOL, V155, P462